MedImmune has announced results from a recent economic analysis of Synagis® (palivizumab), a monoclonal antibody (MAb) that is the standard of care for prevention of severe lower respiratory tract infection due to respiratory syncytial virus (RSV) in high-risk infants. [click link for full article]
(more...)